Neuroendocrine tumors: nursing implications for oral targeted agents and patient management: Part II.
Jacobs
Carmen
C
The Gastrointestinal Medical Oncology Department, The University of Texas M.D. Anderson Cancer Center, Houston, TX, USA. cjacobs@mdanderson.org
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000494:pharmacology* / Q000627:therapeutic use*; D018931:Antineoplastic Agents, Hormonal / Q000627:therapeutic use; D016903:Drug Monitoring; D006801:Humans; D018358:Neuroendocrine Tumors / Q000451:nursing* / Q000473:pathology; D015282:Octreotide / Q000627:therapeutic use; D047428:Protein Kinase Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use*; D011494:Protein Kinases / Q000187:drug effects*; D020123:Sirolimus / Q000031:analogs & derivatives* / Q000494:pharmacology / Q000627:therapeutic use; D058570:TOR Serine-Threonine Kinases
D000970:Antineoplastic Agents; D018931:Antineoplastic Agents, Hormonal; D047428:Protein Kinase Inhibitors; C401859:temsirolimus; D011494:Protein Kinases; C546842:MTOR protein, human; D058570:TOR Serine-Threonine Kinases; D015282:Octreotide; D020123:Sirolimus